Cancer

Arrakis CEO Michael Gilman

Biotech

Drugging the undruggable and other challenges on the road to targeting RNA with pills

By Rebecca Robbins, Adam Feuerstein, and Damian Garde

Biotech

A biotech startup’s lofty goal: Kill cancer with pills that target RNA instead of proteins

By Adam Feuerstein

advertisement

Medicare Part D

First Opinion

Medicare Part D must evolve to help people fight cancer

By Percival Barretto-Ko

advertisement

Nasdaq

Biotech

Watch this company: Turning Point Therapeutics shares pop 57% after IPO

By Matthew Herper

Prostate Cancer Cell

Health

The study of a cancer test seemed like a triumph. But some data were missing

By Eric Boodman

Oxycodone bottles

Pharmalot

After three years of controversy, CDC clarifies its opioid prescribing guidelines

By Ed Silverman

Patrick Soon-Shiong

Pharmalot

A small drug maker accuses Soon-Shiong of masterminding a ‘catch-and-kill’ scheme

By Ed Silverman

advertisement

Probiotics illustration

Health

Probiotics are touted as good for the gut. They may be trouble for the immune system

By Meghana Keshavan

advertisement

Biotech

It’s only test tubes and mice, but Rubius Therapeutics hails first new data on red blood cell-derived cancer drugs

By Adam Feuerstein

Parker Institute for Cancer Immunotherapy

Biotech

The Parker Institute touts early results in pancreatic cancer trial — and a new model to accelerate drug development

By Adam Feuerstein

Alex Trebek

First Opinion

Screening for ‘hidden’ pancreatic cancer can put people in jeopardy

By H. Gilbert Welch

Bristol-Myers Squibb

Pharma

Bristol-Myers Squibb turns to an AI startup to accelerate cancer research

STAT SPOTLIGHT

Biotech

Werewolf moves into a web of immunotherapy startups

By Kate Sheridan

Grady Picture at 2 weeks

Health

A monkey born from frozen testicular tissue offers fertility hope to pediatric cancer survivors

By Andrew Joseph

Empty intravenous pole

First Opinion

Drug shortages jeopardize the lives of children with cancer

By Yoram Unguru

Single vial of blood

First Opinion

Liquid biopsy research should include the perspectives of patients like me

By Grace Cordovano

Plasmodium vivax

Health

An AIDS therapy involving parasite injections was discredited. China is reviving it — for cancer

By Jane Qiu

Norman E. Sharpless

Politics

A believer in biotech and big data: How Ned Sharpless vaulted to the top of the FDA

By Lev Facher and Kate Sheridan

CAR-T

Health

Hospitals are saving lives with CAR-T. Getting paid is another story

By Ike Swetlitz

Breast Cancer Cell

Health

Roche scores first U.S. approval of immunotherapy for breast cancer

By Sharon Begley

Chemotherapy infusion

Pharmalot

Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage

By Ed Silverman

Toilet

First Opinion

New ways to detect cancer early will help pave the way for precision health

By Sanjiv Sam Gambhir

Breast Cancer Cell - pink

First Opinion

Medicare should stop blocking access to next-generation sequencing for people with hereditary cancer

By Roger D. Klein

Da Vinci Surgical Robot

Hospitals

FDA sounds an alarm on using robotic devices in cancer surgeries, citing concerns about safety and results

Blood samples stock

Biotech

Guardant’s blood test might replace biopsies for some lung cancer patients, study says

By Matthew Herper

BiTE Bridge

Pharma

They’re the next new thing in cancer immunotherapy, but will bispecifics help more patients than CAR-Ts?

By Sharon Begley

Adam's Take

Karyopharm hides higher death rate tied to blood cancer drug, dimming approval hopes

By Adam Feuerstein

Investing in health

First Opinion

Impact investing: a new way to fund cures for cancer

By Richard G. Hamermesh and Kathy E. Giusti

Zach Weinberg

Health

Can Roche’s little tech startup help the FDA change clinical trials?

By Matthew Herper